Fosamax Cost in Maine 2026: Alendronate Prices, Insurance, and Medicaid Coverage

What Does Alendronate Actually Cost in Maine in 2026?

Generic alendronate 70 mg tablets, the once-weekly standard dose for osteoporosis, run approximately $15 per month at Maine retail pharmacies in 2026 when paid out of pocket. Brand-name Fosamax carries a manufacturer list price near $80 per month, though almost no cash-paying patient needs to pay that figure given generic availability. The price gap between brand and generic is large enough that most Maine prescribers default to generic from the first prescription.

Alendronate belongs to the bisphosphonate class and was first approved by the FDA in 1995 for postmenopausal osteoporosis [1]. Its mechanism involves binding to hydroxyapatite in bone and inhibiting osteoclast-mediated resorption [2]. The Fracture Intervention Trial (FIT, N=2,027), published in JAMA in 1998, showed alendronate reduced hip fracture risk by 47% and vertebral fracture risk by 55% over three years compared to placebo [3]. That evidence base is why alendronate remains a first-line agent in American Association of Clinical Endocrinology (AACE) guidelines for postmenopausal osteoporosis [4].

Prices vary modestly by pharmacy chain in Maine. Larger chains with discount programs (Walmart, Costco, and independent pharmacies using GoodRx-network pricing) tend to land at $10, $18 per month for a 30-day supply of four 70 mg tablets. Rural Maine pharmacies not connected to major discount networks may price the same supply at $20, $30 before any coupon is applied.

GoodRx and similar coupon aggregators pull real-time negotiated rates across Maine ZIP codes. Searching by specific ZIP code on GoodRx for alendronate 70 mg typically returns the lowest available contracted rate at nearby dispensing pharmacies [5]. That rate is almost always below $20 per month in Maine as of mid-2025.

How MaineCare (Maine Medicaid) Covers Fosamax and Generic Alendronate

MaineCare covers generic alendronate on its preferred drug list with prior authorization (PA) required for most beneficiaries. The PA process asks the prescribing clinician to document a diagnosis of osteoporosis or osteopenia with fracture risk, typically supported by a dual-energy X-ray absorptiometry (DEXA) scan result showing a T-score at or below -2.5, or a T-score between -1.0 and -2.5 with a FRAX 10-year major fracture probability at or above 20% [4].

MaineCare does not cover brand-name Fosamax when a generic equivalent is dispensed. The preferred drug list specifies alendronate sodium as the covered form; brand-name prescriptions are automatically substituted at the pharmacy unless the prescriber marks "dispense as written," which then triggers a separate non-preferred PA pathway.

For MaineCare enrollees, the net out-of-pocket cost after a successful PA approval is typically $0 or a nominal copay of $1, $4 per fill, depending on the beneficiary's specific MaineCare plan tier. Patients in Maine's MaineCare ACO programs may face slightly different formulary structures, so verifying coverage with the specific managed care organization handling their benefits is necessary before assuming $0 cost.

Clinicians submitting PA requests should include the most recent DEXA T-score, FRAX calculation, and any history of fragility fracture. The National Osteoporosis Foundation recommends treatment initiation when the T-score is at or below -2.5 or when a prior hip or vertebral fracture exists [6]. Documenting either criterion clearly in the PA letter shortens approval timelines.

If the PA is denied, MaineCare's appeals process allows a prescriber to submit a peer-to-peer review request within 10 business days of the denial notice. A second denial triggers a formal administrative appeal. The CDC notes that osteoporosis affects an estimated 10 million Americans, with another 44 million having low bone density [7], making successful PA approval a meaningful access issue for Maine's older population.

Is Compounded Alendronate Legal in Maine?

Compounded alendronate is legally dispensed in Maine through state-licensed 503A pharmacies. 503A refers to the section of the Federal Food, Drug, and Cosmetic Act that governs traditional compounding pharmacies operating on a patient-specific prescription basis, distinct from the 503B outsourcing facilities that produce large-volume sterile preparations [8].

A 503A pharmacy in Maine may compound alendronate if a licensed prescriber submits a valid patient-specific prescription and the compounded preparation is not a copy of a commercially available product without clinical justification. Because commercially available alendronate 70 mg tablets exist, a prescriber requesting a compounded version typically must document a clinical reason, for example, a patient who cannot swallow tablets and requires a liquid suspension, or a patient with a documented excipient allergy to the commercial tablet formulation.

The FDA's guidance on compounding from bulk drug substances clarifies that alendronate sodium is not on the list of substances that may not be compounded [9]. Maine's Board of Pharmacy requires compounding pharmacies to meet USP Chapter 795 standards for non-sterile preparations, which covers oral solutions and suspensions of alendronate [10].

The cost of compounded alendronate in Maine ranges from $0 (when covered by a plan that accepts compounded preparations) to modest cash prices that vary by pharmacy. Some MaineCare plans do not cover compounded preparations when a commercially available generic exists, so verifying plan-specific coverage before prescribing a compounded formulation saves the patient a billing surprise.

Patients who genuinely cannot tolerate the tablet formulation should have that clinical rationale documented clearly in the chart, because both MaineCare PA reviewers and commercial plan utilization managers will request it if coverage of a compounded version is sought.

Can Maine Residents Get Alendronate Through Telehealth?

Telehealth prescribing of alendronate is fully legal in Maine as of 2026. Maine law does not restrict prescribing of non-controlled substances via synchronous or asynchronous telemedicine encounters, provided the prescriber holds a valid Maine license or a qualifying out-of-state license recognized under Maine's telemedicine statutes [11].

Federal Ryan Haight Act restrictions apply only to Schedule II, V controlled substances. Alendronate is not a controlled substance, so its prescribing via telehealth does not require an in-person evaluation under federal law. State law similarly imposes no in-person requirement for bisphosphonate prescriptions.

A telehealth clinician prescribing alendronate in Maine will still require a DEXA scan result to confirm the diagnosis and guide dosing decisions. DEXA is not performable via telehealth, so the patient must obtain the scan at an in-person radiology or bone density center. Maine has bone densitometry services available at most major hospital systems, including MaineHealth, Northern Light Health, and Covenant Health, as well as at independent imaging centers throughout the state.

Once DEXA results are shared with the telehealth clinician (via patient portal upload, fax, or integrated health records), the prescription can be issued electronically to any Maine retail or mail-order pharmacy. The entire process from consultation to filled prescription can be completed within one to three business days in most cases.

The American College of Obstetricians and Gynecologists supports telehealth as an appropriate delivery mechanism for osteoporosis screening discussions and medication management in patients with established diagnoses [12]. For patients in rural Maine counties where in-person specialist access is limited, telehealth-based alendronate management is a clinically reasonable pathway.

Which Insurance Plans Cover Fosamax in Maine?

Most commercial insurance plans operating in Maine cover generic alendronate on Tier 1 or Tier 2 of their formularies. Tier 1 placement means a copay of roughly $0, $15 per month; Tier 2 placement typically costs $25, $50 per month. Brand-name Fosamax, if covered at all, usually sits on Tier 3 or Tier 4, which can mean $60, $150 per month in cost-sharing, a strong financial argument for prescribing generic.

Maine's largest commercial insurers, Anthem Blue Cross Blue Shield of Maine, Harvard Pilgrim Health Care, and Community Health Options, all include alendronate on their standard formularies without prior authorization for the generic form in most plan designs. Employer-sponsored self-insured plans may differ; checking the specific plan's Summary of Benefits and Coverage document or calling member services directly provides definitive answers.

Medicare Part D covers generic alendronate on most plan formularies. The Low Income Subsidy (LIS, also called "Extra Help") reduces Part D cost-sharing to $0, $4 per fill for qualifying beneficiaries [13]. Maine residents who are dual-eligible (Medicare and MaineCare) typically pay $0 for alendronate through the Part D Low Income Subsidy.

Patients on Medicare Advantage plans should verify formulary tier and any step-therapy requirements through their plan's Annual Notice of Change or by calling the plan's pharmacy benefit manager directly. Step therapy sometimes requires a trial of a different bisphosphonate before alendronate is covered, though this is uncommon given alendronate's status as the lowest-cost first-line agent.

Savings Programs and the Cheapest Way to Get Fosamax in Maine

The cheapest reliable route for most uninsured or underinsured Maine residents is generic alendronate 70 mg purchased with a GoodRx or RxSaver coupon at a high-volume discount pharmacy [5]. At $10, $18 per month, this approach requires no enrollment, no application, and no PA. The coupon is printed or displayed on a smartphone and presented at the pharmacy counter.

For patients who specifically require brand-name Fosamax, Organon (which now markets Fosamax in the United States following acquisition from Merck) offers a savings card program. The card caps out-of-pocket cost for commercially insured patients, though it does not apply to federal programs including Medicare and Medicaid. Maine residents should check the current Organon Fosamax savings card terms directly at the manufacturer's patient assistance page before relying on a specific dollar amount, as program terms change annually.

The NeedyMeds database lists patient assistance programs for both brand and generic alendronate that provide free or deeply discounted medication to qualifying low-income patients [14]. NeedyMeds is a nonprofit that does not sell data, and its database is updated regularly with program eligibility requirements.

Maine's Drugs for the Elderly and Disabled (DEL) program, administered through the Maine Department of Health and Human Services, may provide additional cost-sharing assistance for qualifying Maine residents who are not fully covered by MaineCare [15]. Eligibility is income-based, and applications are submitted through DHHS.

The table below summarizes the main cost scenarios a Maine patient is likely to encounter:

| Scenario | Estimated Monthly Cost | |---|---| | Generic alendronate, cash price with coupon | $10, $18 | | Generic alendronate, MaineCare (approved PA) | $0, $4 | | Generic alendronate, Medicare Part D LIS | $0, $4 | | Generic alendronate, commercial Tier 1 | $0, $15 | | Brand Fosamax, cash price | ~$80 | | Brand Fosamax, commercial Tier 3, 4 | $60, $150 | | Compounded alendronate, 503A, cash | Varies by pharmacy |

Clinical Dosing and Administration Maine Prescribers Should Confirm

Alendronate for postmenopausal osteoporosis is prescribed at 70 mg orally once weekly or 10 mg orally once daily; the once-weekly regimen is preferred for adherence [2]. For glucocorticoid-induced osteoporosis in men and women, the dose is 5 mg/day (10 mg/day for postmenopausal women not on estrogen) [1].

Administration requires the patient to take the tablet first thing in the morning with 6, 8 oz of plain water, remain upright for at least 30 minutes, and eat nothing else during that window. Deviation from this protocol increases the risk of esophageal irritation, which is the most common reason for patient-reported intolerance [2].

Contraindications include esophageal abnormalities that delay emptying (stricture, achalasia), inability to stand or sit upright for 30 minutes, hypocalcemia, and creatinine clearance below 35 mL/min [1]. Baseline serum calcium and 25-hydroxyvitamin D should be corrected before starting therapy; the Endocrine Society recommends calcium intake of 1,000, 1 to 200 mg/day and vitamin D intake of 1,500, 2 to 000 IU/day as adjuncts to bisphosphonate therapy [16].

The FIT trial found statistically significant fracture risk reduction at three years (P<0.001 for vertebral fractures; P<0.05 for hip fractures), supporting a minimum treatment duration of three years before reassessment [3]. After three to five years of alendronate, a drug holiday may be considered for lower-risk patients, specifically those whose T-score has improved to above -2.5 and who have had no incident fractures, per AACE 2020 guidelines [4].

The HealthRX clinical team has developed a simple three-step framework for Maine telehealth clinicians managing alendronate initiation:

1. Confirm DEXA T-score and FRAX score; document both in the chart.
2. Correct calcium and vitamin D deficiency before writing the alendronate prescription.
3. Send the prescription to the pharmacy the patient identifies as most convenient (or lowest cost via coupon search), and schedule a 90-day follow-up to assess GI tolerability and adherence.

This sequence addresses the two most common reasons alendronate therapy fails in practice: initiating therapy in a hypocalcemic patient (which reduces efficacy) and failing to follow up on GI side effects early enough to intervene before the patient stops taking the medication.

Monitoring, Drug Holidays, and When to Reassess in Maine Patients

After starting alendronate, a follow-up DEXA scan is typically ordered at 24 months to assess treatment response. The Endocrine Society defines a meaningful response as a stable or increasing bone mineral density (BMD) T-score with no incident clinical fracture [16]. Repeat DEXA at 24 months is generally covered by Medicare and most Maine commercial plans for patients with an established osteoporosis diagnosis.

Biochemical markers of bone turnover (serum CTX, P1NP) can be measured at 3 to 6 months to confirm that alendronate is suppressing resorption. Serum CTX should fall by at least 25 to 30% from baseline after three months of consistent therapy [4]. If it does not, the clinician should assess adherence and absorption before assuming treatment failure.

Atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ) are rare but recognized risks with long-term bisphosphonate use. The American Society for Bone and Mineral Research task force estimated AFF incidence at 3.2, 50 per 100,000 person-years, with risk increasing after five years of continuous use [17]. Maine clinicians should document cumulative duration of bisphosphonate exposure in the chart and counsel patients to report new thigh or groin pain promptly.

Drug holiday duration after five years of alendronate therapy typically spans two to three years for lower-risk patients, with annual clinical reassessment [4]. Patients who fractured during therapy, who have T-scores persistently below -2.5, or who have high FRAX scores should generally not take a drug holiday without specialist consultation.